The role of protein kinase C-alpha in hematologic malignancies.
In recent years advances in histopathological and molecular understanding of hematologic malignancies have led to the development of drugs which selectively target proteins associated with hematologic tumorigenesis. One such targeted agent is the antisense oligonucleotide aprinocarsen, which specifically inhibits the signaling protein, protein kinase C-alpha (PKC-alpha). Although PKC-alpha has been associated with tumorigenesis, its role and expression levels in patients with hematologic malignancies are not well understood. We here review studies investigating the expression and role of PKC-alpha in hematologic malignancies. Such a review may offer new insights on how to develop strategies in identifying patients that might best benefit from PKC-alpha inhibition.